Back to results
US 2003/0204073 A1Published application
Non-endogenous, constitutively activated known G protein-coupled receptors
AssigneeArena Pharmaceuticals, Inc.
InventorsKarin Lehmann-Bruinsma, Chen W. Liaw, I-Lin Lin
Life of this patent
Estimating the term…
Abstract
The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (“known GPCRs”), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.
Claims102
A method for directly identifying a non-endogenous compound as a compound having an activity selected from the group consisting of:
- inverse agonists, parallel agonists, and partial agonists, to a non-endogenous, constitutively activated version of known G protein-coupled receptor, said receptor comprising a transmembrane-6 region and an intracellular region, comprising the steps of:
- (a) selecting a non-endogenous version of a known GPCR having an amino acid sequence selected from the group consisting of SEQ.ID.NO.:425;
- 38 SEQ.ID.NO.:427;
- SEQ.ID.NO.:429;
- SEQ.ID.NO.:431;
- SEQ.ID.NO.:433;
- SEQ.ID.NO.:435;
- SEQ.ID.NO.:437;
- SEQ.ID.NO.:439;
- SEQ.ID.NO.:441;
- SEQ.ID.NO.:443;
- SEQ.ID.NO.:445;
- SEQ.ID.NO.:447;
- SEQ.ID.NO.:449;
- SEQ.ID.NO.:451;
- SEQ.ID.NO.:453;
- SEQ.ID.NO.:455;
- SEQ.ID.NO.:457;
- SEQ.ID.NO.:459;
- SEQ.ID.NO.:461;
- SEQ.ID.NO.:463;
- SEQ.ID.NO.:465;
- SEQ.ID.NO.:467;
- SEQ.ID.NO.:469;
- SEQ.ID.NO.:471;
- SEQ.ID.NO.:473;
- SEQ.ID.NO.:475;
- SEQ.ID.NO.:477;
- SEQ.ID.NO.:479;
- SEQ.ID.NO.:481;
- SEQ.ID.NO.:483;
- SEQ.ID.NO.:485;
- SEQ.ID.NO.:487;
- SEQ.ID.NO.:489;
- SEQ.ID.NO.:491;
- SEQ.ID.NO.:493;
- SEQ.ID.NO.:495;
- SEQ.ID.NO.:497;
- SEQ.ID.NO.:499;
- SEQ.ID.NO.:501;
- SEQ.ID.NO.:503;
- SEQ.ID.NO.:505;
- SEQ.ID.NO.:507;
- SEQ.ID.NO.:347;
- SEQ.ID.NO.:509;
- SEQ.ID.NO.:351;
- SEQ.ID.NO.:355;
- SEQ.ID.NO.:359;
- SEQ.ID.NO.:363;
- SEQ.ID.NO.:367;
- SEQ.ID.NO.:371;
- SEQ.ID.NO.:375;
- SEQ.ID.NO.:379;
- SEQ.ID.NO.:383;
- SEQ.ID.NO.:387;
- SEQ.ID.NO.:391;
- SEQ.ID.NO.:511;
- SEQ.ID.NO.:513;
- SEQ.ID.NO.:515;
- SEQ.ID.NO.:517;
- SEQ.ID.NO.:519;
- SEQ.ID.NO.:521;
- SEQ.ID.NO.:523;
- SEQ.ID.NO.:525;
- SEQ.ID.NO.:527;
- SEQ.ID.NO.:529;
- SEQ.ID.NO.:531;
- SEQ.ID.NO.:533;
- SEQ.ID.NO.:535;
- SEQ.ID.NO.:537;
- SEQ.ID.NO.:539;
- SEQ.ID.NO.:541;
- SEQ.ID.NO.:543;
- SEQ.ID.NO.:545;
- SEQ.ID.NO.:547;
- SEQ.ID.NO.:549:
- SEQ.ID.NO.:551;
- SEQ.ID.NO.:553;
- SEQ.ID.NO.:555;
- SEQ.ID.NO.:557;
- SEQ.ID.NO.:559;
- SEQ.ID.NO.:561:
- SEQ.ID.NO.:563:
- SEQ.ID.NO.:565;
- SEQ.ID.NO.:567;
- SEQ.ID.NO.:569;
- SEQ.ID.NO.:571;
- SEQ.ID.NO.:573;
- SEQ.ID.NO.:575;
- SEQ.ID.NO.:577;
- SEQ.ID.NO.:395;
- SEQ.ID.NO.:399;
- SEQ.ID.NO.:403;
- SEQ.ID.NO.:407;
- SEQ.ID.NO.:411;
- SEQ.ID.NO.:415;
- SEQ.ID.NO.:419;
- SEQ.ID.NO.:423;
- SEQ.ID.NO.:579;
- and SEQ.ID.NO.:581;
- (b) confirming that the selected non-endogenous GPCR of step (a) is constitutively active;
- (c) contacting a non-endogenous candidate compound with the non-endogenous, constitutively activated GPCR of step of (b);
- and
- (d) determining, by measurement of the compound efficacy at said contacted receptor, whether said non-endogenous compound having inverse agonist activity as an inverse agonist or agonist activity is an agonist to said receptor of step (b).
101 more elements
Dependencies are inferred from the claim text.